<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5990">
  <stage>Registered</stage>
  <submitdate>12/10/2015</submitdate>
  <approvaldate>12/10/2015</approvaldate>
  <nctid>NCT02577354</nctid>
  <trial_identification>
    <studytitle>ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain</studytitle>
    <scientifictitle>ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain (ReActiv8-B)</scientifictitle>
    <utrn />
    <trialacronym>ReActiv8-B</trialacronym>
    <secondaryid>950057</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Low Back Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - ReActiv8 Implantable Stimulation System (Subject Appropriate Stimulation)
Treatment: devices - ReActiv8 Implantable Stimulation System (Low Stimulation)

Experimental: Treatment - 

Experimental: Control - 


Treatment: devices: ReActiv8 Implantable Stimulation System (Subject Appropriate Stimulation)
ReActiv8 implanted and configured to deliver stimulation at a Subject-appropriate level and subjects instructed to deliver stimulation in two 30-minute sessions per day.

Treatment: devices: ReActiv8 Implantable Stimulation System (Low Stimulation)
ReActiv8 implanted and configured to deliver low stimulation, and subjects instructed to deliver stimulation in two 30-minute sessions per day.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Efficacy Endpoint - Comparison of responder rates for low back pain VAS between Treatment and Control groups.
The Primary Efficacy Endpoint is a comparison of responder rates between Treatment and Control groups, where a "responder" is a Subject with =30% reduction from baseline in average low back pain VAS.</outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Safety Assessment - The primary safety assessment is of serious device and/or procedure related adverse events in all subjects in the Intent to Treat Cohort at the primary Endpoint Assessment visit.</outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Efficacy Endpoint - Comparison of change in Oswestry Disability Index (ODI) between Treatment and Control groups at the Primary End Point Assessment Visit.</outcome>
      <timepoint>4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Efficacy Endpoint - Comparison of change in EQ-5D between Treatment and Control groups at the Primary End Point Assessment Visit.</outcome>
      <timepoint>4 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age =22 years, =75 years

          2. Chronic Low Back Pain that has persisted &gt;90 days prior to the baseline visit.

          3. Continuing low back pain despite &gt;90 days of medical management.

          4. Qualifying pain score.

          5. Qualifying disability score.

          6. Evidence of lumbar multifidus muscle dysfunction.

          7. Be willing and capable of giving Informed Consent.

          8. Ability to comply with the instructions for use and to operate ReActiv8, and to comply
             with this Clinical Investigation Plan.

          9. Suitable for ReActiv8 surgery as determined by the implanting physician prior to
             inclusion.</inclusivecriteria>
    <inclusiveminage>22</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. BMI &gt; 35

          2. Back Pain characteristics:

               1. Any surgical correction procedure for scoliosis at any time, or a current
                  clinical diagnosis of scoliosis.

               2. Lumbar spine stenosis, as defined by an anterior-posterior diameter of the spinal
                  canal of &lt;10mm in subjects with lower extremity pain.

               3. Neurological deficit possibly associated with the back pain (e.g. foot drop).

               4. Back pain due to pelvic or visceral reasons (e.g.: endometriosis or fibroids) or
                  infection (e.g.: post herpetic neuralgia).

               5. Back pain due to inflammation or damage to the spinal cord or adjacent structures
                  (e.g. arachnoiditis or syringomyelia).

               6. Pathology seen on MRI that is clearly identified and is likely the cause of the
                  CLBP that is amenable to surgery.

               7. Back pain due to vascular causes such as aortic aneurysm and dissection.

          3. Any current indication for back surgery according to local institutional guidelines,
             or has indication for back surgery but cannot undergo surgery for other reasons.

          4. Leg pain described as being worse than back pain, or radiculopathy (neuropathic pain)
             below the knee.

          5. Source of pain is the sacroiliac joint as determined by the Investigator.

          6. Drug use.

          7. Surgical and other procedures exclusions.

          8. Any prior diagnosis of lumbar vertebral compression fracture, lumbar pars fracture, or
             lumbar annular tear with disc protrusion that is amenable to surgery.

          9. Planned surgery.

         10. Co-morbid chronic pain conditions.

         11. Other clinical conditions.

         12. Psycho-social exclusions.

         13. Protocol compliance exclusions.

         14. General exclusions.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>128</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Genesis Research Services - Broadmeadow</hospital>
    <hospital>Sunshine Coast Clinical Research - Noosa Heads</hospital>
    <hospital>Pain Medicine of South Australia - Welland</hospital>
    <hospital>Monash Clinical Research - Clayton</hospital>
    <postcode> - Broadmeadow</postcode>
    <postcode> - Noosa Heads</postcode>
    <postcode> - Welland</postcode>
    <postcode> - Clayton</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Sint-Niklaas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Wilrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesbrough</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mainstay Medical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to evaluate the safety and efficacy of ReActiv8 for the
      treatment of adults with Chronic Low Back Pain and no prior spine surgery when used in
      conjunction with medical management.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02577354</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Chris Gilligan, MD, MBA</name>
      <address>Brigham and Women's Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Diane Burnside</name>
      <address />
      <phone />
      <fax />
      <email>diane.burnside@mainstay-medical.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>